Current pricing and reimbursement systems for diagnostics are not efficient. Prices for diagnostics are often driven by administrative practices and expected production cost. The purpose of the paper is to discuss how a value-based pricing framework being used to ensure efficient use and price of medicines could also be applied to diagnostics. Diagnostics not only facilitates health gain and cost savings, but also information to guide patients' decisions on interventions and their future 'behaviors'. For value assessment processes we recommend a two-part approach. Companion diagnostics introduced at the launch of the drug should be assessed through new drug assessment processes considering a broad range of value elements and a balanced analysis of diagnostic impacts. A separate diagnostic-dedicated committee using value-based pricing principles should review other diagnostics lying outside the companion diagnostics-and-drug 'at-launch' situation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pme.12.99 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends and Themes in the Study of Value in Orthopedic Surgery: A Systematic Review.
HSS J
February 2025
Division of Orthopaedic Surgery, McMaster University, Hamilton, ON, Canada.
Background: The study of value in orthopedic surgery aims to maximize health outcomes gained per unit cost through various health economic tools but is fragmented across various subspecialties and geographies. Therefore, it is difficult to ascertain whether this research methodology is being used to its full potential across all orthopedic subspecialties and geographies.
Purpose: We sought to assess the distribution of prior health economics literature in orthopedic surgery across subspecialties and geographies.
The association between clinical trial participation, drug costs, and performance in the Oncology Care Model (OCM).
J Natl Cancer Inst
January 2025
MD Anderson Cancer Center, Houston, TX, USA.
It has long been assumed that academic oncology practices are disadvantaged in value-based payment programs, due to patient complexity and research costs. This assumption not been tested. The Oncology Care Model (OCM) was a Medicare alternative payment model, which sought to curb costs while improving care.
View Article and Find Full Text PDFA Survey of Employed Orthopedic Surgeons Ability to Estimate Operating Room Device Costs.
S D Med
December 2024
Sanford Orthopedics and Sports Medicine, Sioux Falls, South Dakota.
Background: Orthopaedic devices represent a large amount of the overall cost incurred in the operating room. It is unknown if employed sports medicine surgeons are aware of the true prices of these devices. The purpose of this study was to assess sports medicine orthopaedic surgeons' knowledge of implant and device costs, as well of commonly used items in their operating rooms.
View Article and Find Full Text PDFValue-Based Pricing and Its Implications for the Newly Announced Medicare Negotiated Price Under the Inflation Reduction Act.
Diabetes Care
January 2025
Emory Global Diabetes Research Center of the Woodruff Health Sciences Center, Emory University, Atlanta, GA.
Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model.
BMJ Open
January 2025
Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China
Objective: To evaluate the cost-effectiveness of polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) in CD20-positive patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in China.
Design: A Markov model was constructed to analyse the cost-effectiveness of two strategies in CD20-positive patients with previously untreated DLBCL over a lifetime horizon: (1) pola-R-CHP and (2) rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). The clinical outcomes were obtained from the POLARIX(NCT03274492), SCHOLAR-1, ZUMA-7(NCT03391466) and TRANSFORM(NCT03575351) trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!